Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes

The clinical response to cancer therapies involves the complex interplay between the systemic, tumoral, and stromal immune response as well as the direct impact of treatments on cancer cells. Each individual's immunological and cancer histories are different, and their carcinogen exposures may differ. This means that even though two patients with oral tumors may carry an identical mutation in TP53, they are likely to have different pre-existing immune responses to their tumors. These differences may arise due to their distinct accessory mutations, genetic backgrounds, and may relate to clinical factors including previous chemotherapy exposure and concurrent medical comorbidities. In isolation, their cancer cells may respond similarly to cancer therapy, but due to their baseline variability in pre-existing immune responses, patients can have different responses to identical therapies. In this review we discuss how the immune environment of tumors develops, the critical immune cell populations in advanced cancers, and how immune interventions can manipulate the immune environment of patients with pre-malignancies or advanced cancers to improve therapeutic outcomes.

Automated summary

The clinical response to cancer therapies is influenced by the complex interplay between the systemic, tumoral, and stromal immune response, as well as the direct impact of treatments on cancer cells. Differences in immunological and cancer histories, as well as variations in carcinogen exposures, can lead to variability in pre-existing immune responses, resulting in different individual responses to identical therapies. This review discusses the development of the immune environment in tumors, the crucial immune cell populations in advanced cancers, and how immune interventions can improve therapeutic outcomes in patients with pre-malignancies or advanced cancers.